A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b

Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) have become a critical regimen for tumor therapy, but the efficacy of monotherapy is usually limited by drug resistance and multiple angiogenic mechanisms. Complement proteins are becoming potential candidates for cancer-targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huiling, Li, Yiming, Shi, Gang, Wang, Yuan, Lin, Yi, Wang, Qin, Zhang, Yujing, Yang, Qianmei, Dai, Lei, Cheng, Lin, Su, Xiaolan, Yang, Yang, Zhang, Shuang, Li, Zhi, Li, Jia, Wei, Yuquan, Yu, Dechao, Deng, Hongxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940616/
https://www.ncbi.nlm.nih.gov/pubmed/31909182
http://dx.doi.org/10.1016/j.omto.2019.12.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940616/
https://www.ncbi.nlm.nih.gov/pubmed/31909182
http://dx.doi.org/10.1016/j.omto.2019.12.004

Ejemplares similares